Literature DB >> 12040438

Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL).

Y Hatta1, H P Koeffler.   

Abstract

Adult T cell leukemia/lymphoma (ATLL) is one of the peripheral T cell malignant neoplasms strongly associated with human T cell leukemia virus type-I (HTLV-I). Although the viral transactivating protein Tax has been proposed to play a critical role in leukemogeneis as shown by its transforming activity in various experimental systems, additional cellular events are required for the development of ATLL. One of the genetic events in ATLL is inactivation of tumor suppressor genes. Among many candidates for tumor suppressor genes, the main genetic events have been reported to center around the cyclin-dependent kinase inhibitors ((CDKIs) p15INK4A, p16INK4B, p18INK4C, p19INK4D, p21WAF1, p27KIP1, and p57KIP2), p53 and Rb genes; all of them play a major regulatory role during G1 to S transition in the cell cycle. Acute/lymphomatous ATLL has frequent alterations of p15 (20%) and p16 (28-67%), while chronic/smoldering ATLL has fewer abnormalities of p15 (0-13%) and p16 (5-26%). Most of these changes are deletion of the genes; fewer samples have mutations. ATLL patients with deleted p15 and/or p16 genes have significantly shorter survival than those individuals with both genes preserved. Although genetic alterations of p18, p19, p21, p27 have rarely been reported, inactivation of these genes may contribute to the development of ATLL because low expression levels of these genes seem to mark ATLL. The p53 gene is mutated in 10-50% of acute/lymphomatous ATLL. Functional impairment of the p53 protein, even if the gene has wild-type sequences, has been suggested in HTLV-I infected cells. Each of these genetic events are mainly found in acute/lymphomatous ATLL, suggesting that alterations of these genes may be associated with transformation to an aggressive phenotype. The Rb tumor suppressor gene is infrequently structurally altered, but one half of ATLL cases have lost expression of this key protein. Notably, alterations of one of the CDKIs, p53 and Rb genes appear to obviate the need for inactivation of other genes in the same pathway. A novel tumor suppressor gene on chromosome 6q may also have a critical role in the pathogenesis of ATLL. Taken together, tumor suppressor genes are frequently altered in acute/lymphomatous ATLL and their alteration is probably the driving force fueling the transition from chronic/smoldering to acute/lymphomatous ATLL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12040438     DOI: 10.1038/sj.leu.2402458

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

Review 1.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

Review 2.  Adult T cell leukemia lymphoma.

Authors:  Lee Ratner
Journal:  Front Biosci       Date:  2004-09-01

3.  Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.

Authors:  S M Ahmad; S K Larsen; I M Svane; M H Andersen
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

4.  cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response.

Authors:  Harsha S Madapura; Daniel Salamon; Klas G Wiman; Sonia Lain; Eva Klein; Noémi Nagy
Journal:  Cell Cycle       Date:  2016-05-02       Impact factor: 4.534

5.  Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1.

Authors:  Joshua Arnold; Brenda Yamamoto; Min Li; Andrew J Phipps; Ihab Younis; Michael D Lairmore; Patrick L Green
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

6.  IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.

Authors:  Juan Carlos Ramos; Phillip Ruiz; Lee Ratner; Isildinha M Reis; Carlos Brites; Celia Pedroso; Gerald E Byrne; Ngoc L Toomey; Valentine Andela; Edward W Harhaj; Izidore S Lossos; William J Harrington
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 7.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.

Authors:  Andrew Mone; Shannon Puhalla; Susan Whitman; Robert A Baiocchi; Julio Cruz; Tamara Vukosavljevic; Amy Banks; Charles F Eisenbeis; John C Byrd; Michael A Caligiuri; Pierluigi Porcu
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

9.  Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation.

Authors:  Joshua Arnold; Bevin Zimmerman; Min Li; Michael D Lairmore; Patrick L Green
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

10.  Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.

Authors:  Cynthia A Pise-Masison; Michael Radonovich; Kathleen Dohoney; John C Morris; Deirdre O'Mahony; Min-Jung Lee; Jane Trepel; Thomas A Waldmann; John E Janik; John N Brady
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.